|
Mechanism5-HT receptor antagonists [+1] |
|
|
Active Indication- |
|
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismMAO-B inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Double-Blind Randomised Placebo-Controlled Phase I/IIa Dose Titration Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine up to 30 mg vs Placebo BID in Subjects With Urinary Incontinence
This study will explore the safety, tolerability and efficacy of litoxetine in men and women who suffer from urinary incontinence
A Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Phase II, Dose Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of oral Litoxetine 10mg, 20mg and 40mg Twice Daily (BID) versus placebo in women with Mixed Urinary Incontinence
A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Phase 2, Dose Ranging Trial to Evaluate the Efficacy, Safety, and Tolerability of Oral Litoxetine 10mg,20mg and 40mg Twice Daily (BID) versus Placebo in Women with Mixed Urinary Incontinence - IXA-CSP-001 Litoxetine v Placebo in Urinary Incontinence 2016-12-09 V1
100 Clinical Results associated with IXALTIS SAS
0 Patents (Medical) associated with IXALTIS SAS
100 Deals associated with IXALTIS SAS
100 Translational Medicine associated with IXALTIS SAS